Quote:
Originally Posted by Trapper John
The cost and complexity of taking a new drug to market requires the infrastructure of one of the established pharma companies. They're not the bad guys. It's the cost associated with the process. Frankly, I don't see a point to reform without risks such as reduction in drug safety/efficacy
|
I think you forgot the caveat "almost none of this applies to the current batch of COVID vaccines".
